NICE Says Initial No To Epidyolex In England, But GW Pharma Remains Upbeat

Draft guidance from NICE has recommended against the use of GW Pharmaceuticals’ Epidyolex for refractory epilepsy, but the company believes it has the data needed to ensure a positive outcome to the appraisal.

Rejected
NICE has rejected Epidyolex but GW Pharma still hopes for a positive outcome

NICE, the health technology assessment body for England, says that GW Pharmaceuticals’ cannabidiol product Epidyolex together with clobazam is not recommended for use on the National Health Service for patients with treatment-resistant epilepsy.

NICE said it accepted that cannabidiol plus clobazam was a “promising treatment” for seizures associated with Dravet or Lennox-Gastaut syndrome....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe